Amikacin and Vancomycin

The combination of amikacin and vancomycin is an important antibiotic regimen primarily used for serious bacterial infections, particularly those caused by resistant bacteria. This combination demonstrates synergistic bactericidal effects against planktonic bacterial populations, making it more effective than either drug alone. It is especially valuable for treating *Staphylococcus aureus* biofilm infections, where monotherapy shows limited efficacy. Clinical evidence supports its efficacy; a randomized, double-blind trial for febrile, neutropenic children with cancer found a vancomycin-containing regimen (which included amikacin) significantly more effective, with a lower rate of treatment failure compared to a regimen without vancomycin. It remains a crucial option for empirical treatment in settings with serious gram-positive bacteremias, especially in immunocompromised patients. Amikacin, a semi-synthetic aminoglycoside, is effective against resistant gram-negative bacilli such as *Acinetobacter baumanii* and *Pseudomonas aeruginosa*, many aerobic gram-negative bacilli from the Enterobacteriaceae family, and certain *Mycobacterium* species. Vancomycin is effective against gram-positive bacteria. However, a moderate drug interaction risk exists. Both medications can cause hearing loss, tinnitus, vertigo, and kidney problems, and their combination may increase these risks. Careful monitoring is required, especially in elderly patients. Dosing regimens include standard concentrations (e.g., amikacin 70 μg/mL peak with vancomycin 18 μg/mL), with higher amikacin concentrations and continuous vancomycin infusions also studied.